Provide to be used for the treatment of immune disorders, for example autoimmune disease or method for cancer and compositions, it comprises the therapeutic alliance that utilizes the medicament that suppresses the Th17 cell development or keep.Therapeutic scheme is provided, wherein the antagonist of administration proinflammatory cytokine is enough to alleviate autoimmune disease or the symptom of cancer acute stage burst and the time of symptom, and longer time of the treatment of the antagonist of sustainable utilization IL-23 is to prevent the recurrence of acute events.The antagonist that also discloses PGE2 and CD61 is used for the treatment of autoimmunity, inflammatory and proliferative disorders.
